機構股票研究
機構股票研究
機構股票研究
機構股票研究 
 
Page | 1 | PHILLISECURITIES (HK) RESEARCH 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.CH) 
混改落地助力發展新階段
混改落地助力發展新階段
混改落地助力發展新階段
混改落地助力發展新階段 
 
中國
中國
中國
中國 | 醫藥
醫藥
醫藥
醫藥| 公司研報
公司研報
公司研報
公司研報 
 
 
 
6 January 2017 
 
 
品牌延展能力強
品牌延展能力強
品牌延展能力強
品牌延展能力強 
 
雲南白藥原本生產並銷售具有止血功能的抗感染中藥“白藥”，白藥配方為國家
級保密配方，無直接競爭者，定價能力強。近年來，公司積極實施以“藥”為本的
“新白藥、大健康”的發展戰略，重點發展四大業務板塊：藥品板塊以雲南白藥中央/
透皮產品為成熟現金牛品種，普藥則以氣血康口服液、血塞通膠囊的一系列新品推動
穩健增長；健康產品板塊在確保白藥牙膏較快增長的情況下，重點推進養元青洗髮護
髮系列、清逸堂衛生巾系列；中藥資源板塊則利用雲南道地天然植物藥材的資源優勢
構建原材料資源全產業鏈；此外，公司醫藥商業板塊亦不斷通過管道的持續完善為公
司貢獻穩定的收入。 
 
Sales Breakdown in 2015 
 
Source: Company reports, Phillip Securities (HK) Research 
 
值得一提的是，在推動新戰略過程中，公司品牌延展能力凸顯，雲南白藥牙膏已
成為市場份額前三的知名品牌，且是市場份額前五中唯一國產品牌。藉此，公司成為
過去十多年醫藥股中的長跑冠軍。 
 
混改落地助力發展新階段
混改落地助力發展新階段
混改落地助力發展新階段
混改落地助力發展新階段 
 
根據公告，新華都擬向公司控股股東白藥控股增資約人民幣254 億元。交易完成
後，白藥控股的股權結構將由雲南省國資委持有100%股權變更為雲南省國資委和新華
都各持有50%股權，同時，白藥控股仍持有公司41.52%的股份，本次事項亦觸發上市
公司層面的要約收購。  
 
混改完成後，集團控股將由國有獨資變為國有民營混合，並且民營擁有足夠股東
表決話語權，這將令雲南白藥的管理模式趨於靈活和市場化（未來白藥控股的董事、
監事及高級管理人員均以市場化原則進行選聘），並為上市公司未來推進股權激勵奠
定基礎，同時，公司的外延並購亦有望提速，新業務拓展或步入新臺階，未來有望在
精准醫療、養老養生、醫療服務等大健康領域加快佈局，推動公司進入發展新階段。 
買入
買入
買入
買入 (首次
首次
首次
首次) 
現價: CNY 73.90 
(現價截至1 月4 日) 
目標價: CNY 90.60 (+22.6%) 
 
公司資料
公司資料
公司資料
公司資料 
普通股股東 (百萬股) : 
1,041
市值 (人民幣百萬元) : 
76,930
52 周 最高價/最低價 (人民幣元) :
76.15/53.50
 
 
 
 
主要股東
主要股東
主要股東
主要股東， % 
雲南白藥控股有限公司 : 
41.52
 
 
 
股價表現
股價表現
股價表現
股價表現， % 
1 個月
個月
個月
個月
3 個月
個月
個月
個月
1 年
雲南白藥 
6.41
6.41
1.45
滬深300 
9.74
2.05
12.84
 
股價
股價
股價
股價 & 滬深
滬深
滬深
滬深300 
 
Source: Phillip Securities (HK) Research 
 
財務資料
財務資料
財務資料
財務資料 
CNY mn 
FY14
FY15
FY16E
FY17E
Net Sales 
18722 20634
23158 25372
Net Profit 
2506
2771
3077
3430
EPS, CNY 
2.41
2.66
2.95
3.29
PER, x 
30.66
27.78
25.01
22.44
BVPS, CNY 
10.74
12.90
15.25
17.95
P/BV, x 
6.88
5.73
4.84
4.12
ROE, %  
24.80
22.51
20.86
19.73
Debt/Equity (%)
44.68
42.60
42.86
42.86
Source: Company reports, Phillip Securities Est. 
 
研研研研研 
范國和
范國和
范國和
范國和  
(+ 86 21 51699400-110) 
fanguohe@phillip.com.cn 
 
 
 
 
Page | 2 | PHILLISECURITIES (HK) RESEARCH 
雲南白藥
雲南白藥
雲南白藥
雲南白藥（000538 CH）公司研報
公司研報
公司研報
公司研報 
還值一提的是，此次混改觸發了雲南白藥的全面要約收購，且未來不以終
止雲南白藥的上市地位為目的。考慮到收購價格高達64.98 元，僅較停牌前低
6.1%，將為股價提供較強支撐。 
 
估值低於同業
估值低於同業
估值低於同業
估值低於同業 
     
雲南白藥系內地中藥領軍企業，近幾年佈局大健康亦實現明顯成效，而本
次控股股東混改推進速度快、審批效率高均為行業少有，有望成為行業標杆性
事件。考慮公司原主業穩健發展及深厚的品牌資源價值，集團混改又將帶來新
一輪發展機遇，給予其對應2017 年每股收益27.5 倍估值，目標價為90.6 元，
首予“買入”評級。(現價截至1 月4 日) 
 
Historical P/E Valuation 
 
Source: Bloomberg, Phillip Securities (HK) Research 
 
Peer Comparison 
Ticker
Company Name
Mcap (M)
Performance(6M Ret)
P/E(2015) P/E(2016F) P/E(2017F)
600085 CH BEIJING TONGRENTANG CO-A
42,378
5.32%
47.91
43.22
37.55
600436 CH ZHANGZHOU PIENTZEHUANG PHA-A
27,421
2.00%
58.77
46.14
36.65
600557 CH JIANGSU KANION PHARMACEUTI-A
10,806
7.21%
29.63
27.61
23.63
600518 CH KANGMEI PHARMACEUTICAL CO-A
87,467
16.52%
28.38
25.81
21.10
600329 CH TIANJIN ZHONG XIN PHARM CO-A
11,246
4.23%
29.38
28.44
20.99
000423 CH DONG-E-E-JIAOCO LTD-A
35,618
6.19%
21.92
19.61
16.85
002275 CH GUILIN SANJIN PHARMACEUTI-A
10,948
1.59%
29.08
-
-
600535 CH TASLY PHARMACEUTICAL GROUP-A
44,289
15.53%
29.70
29.55
25.60
600252 CH GUANGXI WUZHOU ZHONGHENG G-A
15,985
6.22%
30.67
-
-
Average
31,795
7.20%
33.94
31.48
26.05
000538 CH YUNNAN BAIYAO GROUP CO LTD-A
77,314
16.69%
26.77
25.00
21.80  
Source: Bloomberg, Phillip Securities (HK) Research 
 
風險
風險
風險
風險 
 
日化產品增速低於預期； 
主要原材料價格上漲； 
國企改革效果低於預期。 
 
 
 
 
 
 
Page | 3 | PHILLISECURITIES (HK) RESEARCH 
雲南白藥
雲南白藥
雲南白藥
雲南白藥（000538 CH）公司研報
公司研報
公司研報
公司研報 
 
財務報告
財務報告
財務報告
財務報告 
 
Periodicity:
Periodicity:
Periodicity:
Periodicity:
2013
2013
2013
2013
2014
2014
2014
2014
2015
2015
2015
2015
2016F
2016F
2016F
2016F
2017F
2017F
2017F
2017F
Price Earnings
33.19
30.66
27.78
25.01
22.44
Price to Book
8.52
6.88
5.73
4.84
4.12
Dividend Yield
0.45%
0.68%
0.81%
0.81%
0.89%
EPS Adjusted
2.23
2.41
2.66
2.95
3.29
Book Value Per Share
8.67
10.74
12.90
15.25
17.95
Dividends Per Share
0.33
0.50
0.60
0.60
0.66
Revenue growth
14.51%
18.96%
10.21%
12.23%
9.56%
Gross profit growth
11.29%
20.84%
11.55%
11.55%
9.25%
Net profit growth
46.71%
7.95%
10.56%
11.06%
10.29%
Gross Margin
29.36%
29.82%
30.18%
30.00%
30.20%
Operating Margin
12.47%
14.63%
14.57%
14.40%
14.60%
Net Profit Margin
14.75%
13.39%
13.43%
13.29%
13.52%
Dividend Payout Ratio %
14.97%
20.75%
22.56%
20.31%
20.04%
Return on Assets
19.72%
17.15%
15.55%
14.61%
13.81%
Return on Equity
28.92%
24.80%
22.51%
20.86%
19.73%
Liability ratio
29.91%
30.88%
29.87%
30.00%
30.00%
Effective Tax Rate
14.06%
14.19%
14.30%
14.20%
14.20%
Revenue
Revenue
Revenue
Revenue
15,738
15,738
15,738
15,738
18,722
18,722
18,722
18,722
20,634
20,634
20,634
20,634
23,158
23,158
23,158
23,158
25,372
25,372
25,372
25,372
     - Cost of Goods Sold
11,118
13,139
14,406
16,210
17,710
Gross Income
Gross Income
Gross Income
Gross Income
4,620
4,620
4,620
4,620
5,583
5,583
5,583
5,583
6,228
6,228
6,228
6,228
6,947
6,947
6,947
6,947
7,662
7,662
7,662
7,662
     - Selling, General & Admin Expenses
2,658
2,844
3,221
3,613
3,958
Operating Income
Operating Income
Operating Income
Operating Income
1,962
1,962
1,962
1,962
2,739
2,739
2,739
2,739
3,006
3,006
3,006
3,006
3,335
3,335
3,335
3,335
3,704
3,704
3,704
3,704
     - Interest Expense
21
46
79
70
60
     - Net Non-Operating Losses (Gains)
-764
-217
-284
-300
-330
Pretax Income
2,701
2,910
3,215
3,567
3,974
     - Income Tax Expense
380
413
460
506
564
Income Before XO Items
2,321
2,497
2,756
3,060
3,410
     - Minority Interests
0
-9
-15
-17
-20
Net Profit
Net Profit
Net Profit
Net Profit
2,321
2,321
2,321
2,321
2,506
2,506
2,506
2,506
2,771
2,771
2,771
2,771
3,077
3,077
3,077
3,077
3,430
3,430
3,430
3,430
Income Statement(CNY: mn)
Income Statement(CNY: mn)
Income Statement(CNY: mn)
Income Statement(CNY: mn)
Valuation Ratios
Valuation Ratios
Valuation Ratios
Valuation Ratios
Per share data(CNY)
Per share data(CNY)
Per share data(CNY)
Per share data(CNY)
Growth & Margin
Growth & Margin
Growth & Margin
Growth & Margin
Key ratios
Key ratios
Key ratios
Key ratios
Source: Company, Phillip Securities (HK) Research Estimates 
(財務資料截至1 月4 日) 
  
 
 
 
 
 
 
 
 
 
 
 
 
PHILL
 
雲南白藥
雲南白藥
雲南白藥
雲南白藥（000538 CH）公司研報
公司研報
公司研報
公司研報 
PHILLIP RESEARCH STOCK SELECTION SYSTEMS 
 
We do not base our recommendations entirely on the above quantitative return bands.  We consider qualitative factors like (but not limited to) a 
stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative 
undertones surrounding the stock, before making our final recommendation 
 
GENERAL DISCLAIMER 
This publication is prepared by Phillip Securities (Hong Kong) Ltd (“Phillip Securities”). By receiving or reading this publication, you agree to be bound by the terms and 
limitations set out below. 
 
This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or 
consequential loss arising from any use of material contained in this publication. 
 
The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, 
forecasts, projections, expectations and opinions (collectively the “Research”) contained in this publication are based on such information and are expressions of belief 
only. Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, 
complete or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not 
have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will 
Phillip Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made 
available, even if it has been advised of the possibility of such damages. 
 
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time 
without prior notice. 
 
This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any 
particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a 
financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, 
before making a commitment to invest in any of such products. 
This publication should not be relied upon as authoritative without further being subject to the recipient’s own independent verification and exercise of judgment. The 
fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product 
described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication 
involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all 
such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein 
with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks. 
 
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research 
should take into account existing public information, including any registered prospectus in respect of such security. 
 
Disclosure of Interest 
Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in 
this report. 
Firm’s Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or 
more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation. 
 
Availability 
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where 
such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or 
licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction. 
 
Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited (“PSHK”) believed to be accurate. PSHK does not bear responsibility for any 
loss occasioned by reliance placed upon the contents hereof.  PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of 
different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk.   
© 
2017 Phillip Securities (Hong Kong) Limited 
 
Contact Information (Regional Member Companies) 
Total Return 
Recommendation 
Rating 
Remarks 
>+20% 
Buy 
1 
>20% upside from the current price 
+5% to +20% 
Accumulate 
2 
+5% to +20%upside from the current price 
-5% to +5% 
Neutral 
3 
Trade within  ± 5% from the current price 
-5% to -20% 
Reduce 
4 
-5% to -20% downside from the current price 
<-20% 
Sell 
5 
>20%downside from the current price 
 
 
 
PHILL
 
雲南白藥
雲南白藥
雲南白藥
雲南白藥（000538 CH）公司研報
公司研報
公司研報
公司研報 
SINGAPORE 
Phillip Securities Pte Ltd 
Raffles City Tower 
250, North Bridge Road #06-00 
Singapore 179101 
Tel : (65) 6533 6001 
Fax : (65) 6535 6631 
Website: www.poems.com.sg 
MALAYSIA 
Phillip Capital Management Sdn Bhd 
B-3-6 Block B Level 3 Megan Avenue II, 
No. 12, Jalan Yap Kwan Seng, 50450 
Kuala Lumpur 
Tel (603) 21628841 
Fax (603) 21665099 
Website: www.poems.com.my 
 
HONG KONG 
Phillip Securities (HK) Ltd 
Exchange Participant of the Stock Exchange of Hong Kong 
11/F United Centre 95 Queensway 
Hong Kong 
Tel (852) 22776600 
Fax (852) 28685307 
Websites: www.phillip.com.hk 
 
JAPAN 
PhillipCapital Japan K.K. 
Nagata-cho Bldg., 
8F, 2-4-3 Nagata-cho, 
Chiyoda-ku, Tokyo 100-0014 
Tel (81-3) 35953631 
Fax (81-3) 35953630 
Website:www.phillip.co.jp 
 
INDONESIA 
PT Phillip Securities Indonesia 
ANZ Tower Level 23B, 
Jl Jend Sudirman Kav 33A 
Jakarta 10220 – Indonesia 
Tel (62-21) 57900800 
Fax (62-21) 57900809 
Website:www.phillip.co.id 
 
CHINA 
Phillip Financial Advisory (Shanghai) Co. Ltd 
No 436 Hengfeng Road, 
Greentech Unit 604, 
Postal code 200070 
Tel (86-21) 51699400 
Fax (86-21) 63532643 
Website: www.phillip.com.cn 
 
THAILAND 
Phillip Securities (Thailand) Public Co. Ltd 
15th Floor, Vorawat Building, 
849 Silom Road, Silom, Bangrak, 
Bangkok 10500 Thailand 
Tel (66-2) 6351700 / 22680999 
Fax (66-2) 22680921 
Websitewww.phillip.co.th 
 
FRANCE 
King & Shaxson Capital Limited 
3rd Floor, 35 Rue de la Bienfaisance 75008 
Paris France 
Tel (33-1) 45633100 
Fax (33-1) 45636017 
Website: www.kingandshaxson.com 
 
UNITED KINGDOM 
King & Shaxson Capital Limited 
6th Floor, Candlewick House, 
120 Cannon Street, 
London, EC4N 6AS 
Tel (44-20) 7426 5950 
Fax (44-20) 7626 1757 
Website: www.kingandshaxson.com 
 
UNITED STATES 
Phillip Futures Inc 
141 W Jackson Blvd Ste 3050 
The Chicago Board of Trade Building 
Chicago, IL 60604 USA 
Tel +1.312.356.9000 
Fax +1.312.356.9005 
 
AUSTRALIA 
PhillipCapital Australia 
Level 12, 15 William Street, 
Melbourne, Victoria 3000, Australia 
Tel (613) 96188238 
Fax (613) 92002272 
Website: www.phillipcapital.com.au 
 
 
